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INTRODUCTION
The need of adapting healthcare systems (originally designed for younger patients with a lower
burden of chronic conditions) to the specific needs of older individuals has been repeatedly evoked
in light of the rapid aging of our populations (Beard et al., 2016; Cesari et al., 2016a). In this scenario,
the so-called “frailty” condition has been attracting special interest. The concept of frailty is today
no longer confined within the original geriatric boundaries, being currently implemented in various
medical areas, from cardiology (Afilalo et al., 2009) to anesthesiology (Hubbard and Story, 2014),
from infectious disease medicine (Brothers et al., 2014) to oncology (Balducci, 2013). It is indeed
growingly considered as a crucial aspect for reshaping our healthcare systems, as requested by
public health agencies (European Commission, 2015).
DEFINITION OF FRAILTY
Frailty is a geriatric condition characterized by the reduction of the individual’s homeostatic
reserves, leading to an increased vulnerability to endogenous and exogenous stressors (Morley et al.,
2013). It is a strong predictor of health-related events (including functional decline, hospitalization,
institutionalization, and death; Clegg et al., 2013). It is considered as resulting from the interaction
between the progressive age-related decline in physiologic systems and chronic diseases and
conditions, consequently leading to decreased functional reserve capacities (Cesari et al., 2016a).
Although there is a large agreement around the theoretical definition of frailty, multiple
instruments have been developed with the aim of capturing and objectivating such state of
increased vulnerability. Consequently, the estimates of frailty prevalence are largely dependent on
the adopted operational definitions and vary substantially across available studies (Collard et al.,
2012; Theou et al., 2015).
IMPLICATIONS OF FRAILTY IN THE APPROACH TO COGNITIVE
DISORDERS
Despite its scientific and clinical relevance, the concept of frailty is still rarely adopted in
neurological settings and, in particular, in the field of cognitive disorders (Canevelli et al., 2014).
This is quite surprising if considering that cognitive skills and capacities are recognized as
strong contributors to the individual’s vulnerability and resiliency to stressors, and that cognitive
symptoms and disturbances become highly prevalent within the aging process (Canevelli et al.,
2014).
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The frailty construct may have important implications in
the routine clinical approach to subjects attending clinical
centers dedicated to the management of cognitive disturbances
(i.e., memory clinics). First, it may consent to properly
and multidimensionally consider the overall health status
of the aging individual, thus not neglecting those “non-
neurological” aspects (from sleep disorders to depression, from
nutritional deficiencies to social issues, from polypharmacy to
multimorbidity) potentially causing or contributing to the onset
and progression of cognitive symptoms (Canevelli et al., 2015).
This broader and holistic viewpoint is today required by the
complexity of age-related pathological conditions (as cognitive
disorders are; Canevelli et al., 2015), which are determined
by multiple, simultaneous, and interacting pathophysiological
processes. Promoting such approach does not automatically
imply lower importance to those aspects that have traditionally
and virtuously characterized the neurological practice (i.e., the
accurate study of the neuronal and brain processes underlying
the cognitive disturbances). It simply means integrating pivotal
information about the heterogeneous aging of the individual.
At the same time, an improved discrimination of true
neurodegenerative conditions from the disturbances caused by
the disruption of the homeostatic balance (indirectly responsible
for the cognitive impairment) will have immediate impact in
the clinical and research strategies (Cesari and Canevelli, 2014).
For example, the assessment of frailty may provide useful
indications for better planning and implementing individualized
preventive and/or therapeutic interventions as well as support a
more accurate prevision of the cognitive disturbance trajectory
(Robertson et al., 2013). Weighting the overall clinical burden of
the individual may also help at better distributing resources and
improving the allocation of care services (Cesari et al., 2016b).
Or, filtering the recruitment of participants in a clinical trial
with a frailty assessment will allow maximizing the effect size
of the interventions by selecting more or less “pure” individuals
presenting a certain condition of risk.
INSTRUMENTS FOR ASSESSING FRAILTY
To date, there are more than 60 instruments available in
literature for measuring frailty (Buta et al., 2016). The majority
of them have been designed as screening instruments. Therefore,
they may serve for the initial risk stratification of populations
(Cesari et al., 2014). Conversely, the Frailty Index [proposed and
validated by Rockwood and colleagues in the Canadian Study of
Health and Aging (CSHA); Rockwood et al., 2005] is inapplicable
at the first contact with an individual, and it can only be generated
after (or in parallel with) a comprehensive clinical assessment
(Cesari et al., 2014).
The Frailty Index may open interesting and promising
scenarios in the field of neurodegenerative diseases and cognitive
disorders (Kelaiditi et al., 2016). This instrument has been
designed on an arithmetical model of “deficit accumulation;” i.e.,
the more deficits a person has, the more that person will be frail
(Mitnitski et al., 2001; Rockwood and Mitnitski, 2012). Thus, it
might be considered as an objective marker of “biological aging.”
The Frailty Index is composed by a checklist of non-predefined
variables (i.e., deficits) constituted by symptoms, signs, diseases,
disabilities, and laboratory findings. The Frailty Index is simply
the ratio between deficits presented by the individual and the
total number of deficits considered [thus providing a continuous
measure of frailty ranging between 0 (absence of frailty) and
1 (maximum of frailty); Searle et al., 2008]. Estimates of risk
have been reported to be robust when a minimum set of 50
heterogeneous and multidimensional variables are considered.
However, shorter versions (as low as composed by 20 items) have
also been used in the literature (Searle et al., 2008).
Following a standard procedure (Searle et al., 2008), a Frailty
Index can be retrospectively computed from available databases,
even if these were created for completely different purposes. It
is only important that the deficits to be considered are age-
related, multidimensional (thus referring to different domains of
the individual’s health status), associated with negative outcomes,
and not saturate too early or too late (i.e., being too highly
or lowly prevalent in most people by some age; Searle et al.,
2008). Since the Frailty Index weights every composing item
as 1/n (where n is the total of considered deficits), no specific
sign, symptom, or condition will be able to affect/bias the final
score. At the same time, one item will become relevant if
associated with other (more or less related) signs, symptoms,
and/or conditions. In other words, the issue of standardizing
different items in different settings is here resolved through
the standardization and harmonization of the approach to the
biological phenomenon, by using a mathematical model. Finally,
by including disabilities in its computation, the Frailty Index
provides meaningful results in every individual, independently of
age and functional status. This solves the issue of a possible ceiling
effect present in many tools designed for measuring frailty.
The Frailty Index has demonstrated consistent characteristics
across samples and settings (Clegg et al., 2013). It has shown
to increase with age, be strongly associated with negative health
outcomes, and report higher values in women than in men (Peña
et al., 2014). Given its continuous nature, the Frailty Index is also
particularly sensitive to modifications over time and avoids the
introduction of arbitrary decisions for the choice of defining cut-
points (Rockwood et al., 2007). Thus, it may constitute a useful
tool for describing the overall health status of the individual and
measure its trajectory over time (also to ascertain the effectiveness
of the implemented interventions; Cesari et al., 2014).
In light of its properties, the Frailty Index seems more
appropriate to be adopted in the approach to subjects
with cognitive disturbances in comparison to other available
instruments developed to assess frailty. Differently from other
operationalizations, the index is not based on a fixed set
of criteria but on a quantitative/mathematic model. Thus,
it can be computed, even retrospectively, from existing
datasets and available clinical information. In parallel, it does
not require the adoption of specific tests (e.g., assessment
of physical performance), tools (e.g., dynamometers), and
ad hoc questionnaires, potentially resulting in costly and
time-consuming procedures. Conversely, it can be directly
implemented in the clinical practice without requiring changes
in the routine/standard approach to patients. This aspect appears
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to be crucial in the context of cognitive disturbances, considering
that cognitive deficits may impair an individual’s ability to
perform specific tests and/or provide consistent answers about
perceived symptoms or behavior. Finally, being founded on
objective criteria, the Frailty Index is less prone to generate biases
arising from the modification of pre-existing questionnaires and
tools, as observed for other operational definitions (Theou et al.,
2015).
The Frailty Index has already been cross-sectionally evaluated
in studies exploring cognitive outcomes. In particular, it was
found to be associated with poorer global cognitive performance
(Rockwood et al., 2007), greater impairment in specific cognitive
domains [such as neurocognitive speed (Rolfson et al., 2013)
and executive functioning (Langlois et al., 2012)], and higher
dementia prevalence (Armstrong et al., 2010).
More recently, the Frailty Index has been introduced for
predicting the incidence of negative outcomes in neurology.
Song and colleagues calculated a Frailty Index composed by
deficits not known to predict dementia (e.g., fractures, cough,
skin, and dental problems...) in 7,239 cognitively healthy,
community-dwelling older adults in the CSHA (Song et al.,
2011). This tool resulted to be significantly associated with
the incidence of Alzheimer’s disease (AD) and dementia of all
types over 5- and 10-year follow-up periods. These associations
were confirmed even after adjusting for age and traditional
risk factors. Interestingly, each accumulated deficit increased
the odds ratio of dementia by 3.2%. The Frailty Index also
significantly discriminated people with dementia from those who
were cognitively healthy.
A Frailty Index has recently been retrospectively computed
and adopted in the Impact of Cholinergic Treatment USe
(ICTUS) study, enrolling 1,375 mild to moderate AD
patients across 12 European countries. In a first post-hoc
analysis, a 30-item Frailty Index resulted to be significantly
associated with mortality and hospitalization after 2 years of
follow-up, exhibiting a borderline significance also for the
institutionalization endpoint (Kelaiditi et al., 2015). In the same
cohort of patients, the Frailty Index was found to strongly predict
the rate of cognitive decline as measured by the modifications
of the Mini Mental State Examination (MMSE) and Alzheimer’s
Disease Assessment Scale–Cognitive subscale (ADAS-Cog)
scores (Kelaiditi et al., 2016). In particular, the presence of
additional item (equivalent to a 3.3% increase in the Frailty
Index) was associated with a clinically meaningful worsening
of cognitive performance as indicated by a decline of 2.63 and
6.96 points in the MMSE and ADAS-Cog scores after 1 year
of follow-up. Along the same lines, in the CSHA and in the
Honolulu-Asia Aging Study, cognitive changes (measured by
Modified Mini Mental State Examination and by the Cognitive
Abilities Screening Instrument, respectively) were significantly
influenced by the baseline Frailty Index (Mitnitski et al., 2011a,b;
Armstrong et al., 2016). Accordingly, frail people were less
likely to show cognitive improvement or stabilization over time
compared to non-frail participants.
Based on these considerations, the Memory Clinic of the
“Sapienza” University of Rome (Italy) has recently decided to
systematically implement the Frailty Index, building it from
TABLE 1 | Example of the 50 items composing the Frailty Index currently
used at the Memory Clinic of the “Sapienza” University of Rome.
50-ITEM FRAILTY INDEX
Osteoporosis
Hypertension
Arthritis
Gastric disorder
Intestinal disorder
Ischemic heart disease
Chronic heart failure
Arrhythmia
History of stroke
History of TIA
Diabetes
Renal failure
Thyroid disease
Cancer
Cirrhosis
Peripheral artery disease
COPD
Dyslipidemia
Falls
Vertigo
Balance disorders
Involuntary weight loss (≥4.5 kg in the last 6 months)
Obesity (BMI ≥ 30 kg/m2)
Underweight (BMI < 18.5 kg/m2)
Focal neurological signs
Parkinsonism
Peripheral neuropathy
Depression
Anxiety
Sleep disorders
Memory complaint
Language disturbances
Spatiotemporal disorientation
Hearing impairment
Urinary incontinence
Mobility disability (inability to walk 400 m)
Hep with drugs (IADL)
Help with shopping (IADL)
Help with money (IADL)
Help with telephone (IADL)
Help with transportation (IADL)
Help toileting (ADL)
Help eating (ADL)
Help dressing (ADL)
Help transferring (ADL)
Hemoglobin (<13.5 g/dL in males; <12.0 g/dL in females)
Creatinine (<0.6 mg/dL)
Albumin (<3.5 g/dL)
Folic acid (<2.7 ng/ml)
White blood cells (<4 × 103/mm3 )
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signs, symptoms, and conditions that are routinely checked
in all the individuals referring to its service for evaluation of
cognitive disturbances. Thus, its computation does not imply
any modification of the daily clinical practice. The detailed list
of deficits composing the instrument is presented in Table 1 just
as an example, in order to underline how a Frailty Index can be
created in every clinical setting.
CONCLUSIONS
The assessment of frailty may significantly improve the clinical
and research approach to cognitive disturbances, also facilitating
amore balanced and holistic understanding of these complex and
burdening problems. In this regard, further research is needed in
order to disentangle the complex network of pathophysiological
mechanisms potentially affecting both cognition and individual
vulnerability/resiliency. The Frailty Index may respond to the
need of adjusting standard instruments to the heterogeneous
population of subjects with cognitive disturbances, adding a
useful estimate of the individual’s biological aging to the other
traditional neurological and cognitive evaluations.
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